Q-omics provides the consensus-scored CICP27 profile across patient tissues and cancer cell-line models. CICP27 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CICP27 is differentially expressed in 6, with the highest sampling consensus in LIHC. Additionally, CICP27 RNA expression shows 9,761 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, and TGCT as cancer lineages where CICP27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CICP27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CICP27 survival associations across molecular data types. CICP27 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CICP27 RNA expression–survival associations across cancer types. High CICP27 expression shows unfavorable associations in LIHC, KIRC, BRCA, UVM, KICH and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CICP27 RNA expression.
This table summarizes CICP27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CICP27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CICP27 shows lower tumor expression in KICH and COAD and higher tumor expression in LIHC, CHOL, UCEC and STAD. The LIHC box plot shows higher CICP27 RNA expression in tumor versus normal tissue (log2 FC = +0.025, t-test p = .001).
This table shows molecular features associated with CICP27 in patient tissues and cancer cell lines. In patient samples, CICP27 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
